Dobutamine
Dobutrex (dobutamine) is a small molecule pharmaceutical. Dobutamine was first approved as Dobutrex on 1982-01-01. It is used to treat low cardiac output in the USA. The pharmaceutical is active against beta-1 adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dobutamine | ANDA | 2023-05-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| low cardiac output | — | D002303 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1250 | Injection, dobutamine hydrochloride, per 250 mg |
| S9348 | Home infusion therapy, sympathomimetic/inotropic agent infusion therapy (e.g., dobutamine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | 2 | 13 | 15 |
| Astigmatism | D001251 | H52.2 | — | — | — | 1 | 2 | 3 | |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | 1 | 1 | 2 |
| Macular edema | D008269 | — | — | — | 1 | — | 1 | ||
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | — | 3 | — | — | 3 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | — | 3 | — | — | 3 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Presbyopia | D011305 | H52.4 | — | — | — | — | 5 | 5 | |
| Intraocular lenses | D007910 | — | — | — | — | 3 | 3 | ||
| Myopia | D009216 | H52.1 | — | — | — | — | 2 | 2 | |
| Pseudophakia | D019591 | — | — | — | — | 2 | 2 | ||
| Descemet stripping endothelial keratoplasty | D057111 | — | — | — | — | 1 | 1 | ||
| Hydrophilic contact lenses | D003263 | — | — | — | — | 1 | 1 | ||
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | — | 1 | 1 |
| Vitreous hemorrhage | D014823 | EFO_0008626 | H43.1 | — | — | — | — | 1 | 1 |
| Epiretinal membrane | D019773 | HP_0100014 | — | — | — | — | 1 | 1 | |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DOBUTAMINE |
| INN | dobutamine |
| Description | Dobutamine is a catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure. It has a role as a cardiotonic drug, a sympathomimetic agent and a beta-adrenergic agonist. It is a secondary amine and a catecholamine. |
| Classification | Small molecule |
| Drug class | β1-agonist |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 34368-04-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL926 |
| ChEBI ID | 4670 |
| PubChem CID | 36811 |
| DrugBank | DB00841 |
| UNII ID | 3S12J47372 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,707 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more